Indelicato J M, Fisher J W, Pasini C E
J Pharm Sci. 1986 Mar;75(3):304-6. doi: 10.1002/jps.2600750321.
The potentially orally bioavailable arylglycine-substituted monobactam, (2S,3S)- 3-[(2R)-2-amino-2-phenylacetamido]-2-methyl-4-oxo-1- azetidinesulfonic acid, was prepared as a crystalline solid. No significant antibacterial activity [i.e., MICs were greater than 128 (micrograms/mL)] was found when the monobactam was tested against Gram positive and Gram negative bacteria. Solution instability (greater than 2,000 times less stable than aztreonam) due to intramolecular nucleophilic amine attack on the beta-lactam is believed to be a contributing factor to the poor microbiological activity.
潜在口服生物可利用的芳基甘氨酸取代单环β-内酰胺,即(2S,3S)-3-[(2R)-2-氨基-2-苯基乙酰胺基]-2-甲基-4-氧代-1-氮杂环丁烷磺酸,被制备成结晶固体。当该单环β-内酰胺针对革兰氏阳性菌和革兰氏阴性菌进行测试时,未发现显著的抗菌活性[即最低抑菌浓度大于128(微克/毫升)]。由于分子内亲核胺对β-内酰胺的攻击导致的溶液不稳定性(比氨曲南稳定性低2000倍以上)被认为是微生物活性较差的一个促成因素。